BG Medicine

The company said that it has amended its licensing deal with Abbott in anticipation of the US launch of it automated galectin-3 test.

BG Medicine has sold secured convertible promissory notes for $500,000 and has agreed to sell $2 million of newly created Series A preferred stock. 

The company also said that its full-year 2014 revenues dropped 32 percent year over year. 

The company said that it will request a hearing at which it will present its plan to regain and maintain compliance with the applicable listing requirements.

The company has until March 4 to meet the requirement for minimum stock price and until May 19 to meet the requirement for minimum market capitalization.

From research collaborations to corporate acquisitions, attention from the broader scientific community highlighted the field's capabilities and limitations.

The company has failed to meet the minimum $2.5 million in stockholders' equity required for listing on the exchange.

NEW YORK (GenomeWeb News) – BG Medicine today reported third quarter revenues of $695,000, down 31 percent from $1 million in the third quarter of 2013.

NEW YORK (GenomeWeb) – BG Medicine, which said last month it had laid off more than half of its staff, said in a regulatory document on Friday that it has suspended further payments to its non-employee board directors, effective Oct. 1.

Protein analysis firm Zephyrus Biosciences launched this week with Kelly Gardner as CEO, Josh Molho as chief technology officer, Brock Siegel as chief operating officer, Gary Zweiger as chief business development officer, Jenny Rooke as chief marketing officer, and Chris Hadsell as chief financia

Pages

An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.